RESOLVA INSIGHTS

China AI-Powered Healthcare Diagnostics Infrastructure Platform Feasibility Study with HealthTech Market Forecast

Executive Viability Abstract

This feasibility study evaluates the establishment of a large-scale, AI-driven diagnostic infrastructure platform in China. The project aims to bridge the diagnostic gap between Tier 1 urban hospitals and Tier 2/3 regional facilities by deploying cloud-native AI models for oncology, cardiology, and respiratory imaging. With a CAGR of 38.5% in the Chinese HealthTech sector, the platform leverages government mandates for 'Digital China' and 'Healthy China 2030' to capture significant market share in the automated screening and diagnostic assistance segment.

Return on Investment
142% over 5 years
Payback Span
3.8 years
Net Present Value
$118,400,000
IRR Index
28.5%
## Market Analysis China's AI healthcare market is projected to reach $5.9 billion by 2025. The primary drivers are an aging population (200m+ over 65) and a chronic shortage of specialized radiologists. The 'Internet + Healthcare' policy framework provides a favorable regulatory environment for remote diagnostic platforms. Key competitors include regional players like Infervision and United Imaging, but a centralized infrastructure platform offering 'AI-as-a-Service' (AIaaS) remains a high-entry-barrier opportunity. ## Capex Summary Initial capital expenditure is estimated at $45.5M. This includes: - GPU-accelerated Data Centers (Tier 3+): $22M - R&D and NMPA Class III Certification costs: $12M - Hospital Information System (HIS) / PACS integration middleware: $6.5M - Operational setup and legal compliance (PIPL/DSL): $5M. ## Revenue Model The platform will utilize a hybrid monetization strategy: - **Transactional Model:** $2.50 - $10.00 per diagnostic scan. - **SaaS Subscription:** Tiered monthly fees for regional hospital groups ($15k - $50k/month). - **Data Insights:** Anonymized longitudinal data licensing for pharmaceutical R&D. ## Financial Projections Year 1 focuses on infrastructure and pilot programs. Year 3 expects to reach 500+ integrated hospitals. By Year 5, gross margins are projected at 72% due to the scalability of cloud-based inference.